Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial

Abdelalim, Abdelrahman Ahmed; Mohamady, Ayman Abdelaal; Elsayed, R.A.; Elawady, Mona Ahmed; Ghallab, Abdelhakim Fouad

doi:10.1016/j.amjoto.2020.102884

Cited by 126 publications

(196 citation statements)

References 19 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…The patients were assigned to a topical corticosteroid group (100 mcg daily) or a control group for three weeks. The results showed that the use of intranasal corticosteroid offered no benefits over olfactory training, and the median smell scores according to VAS at weekly assessment showed significant recovery rate in each group (P < 0.001) without any significant differences between the two groups [17] . Similar to our study, the authors administered mometasone furoate as local corticosteroid to improve olfactory dysfunction.…”

Section: Discussionmentioning

confidence: 85%

“…Moreover, dissimilar patient settings from home isolation (mild COVID-19) to hospitalization (moderate-severe) might have affected patient outcomes. Consequently, it is not possible to establish whether patients experienced improvement due to the applied intervention and not the normal course of COVID-19 in the study of Abdelalim et al [17] . In contrast, we studied the patients with anosmia or severe microsmia as confirmed by the SIT test, and not only through self-reported olfactory loss.…”

Section: Discussionmentioning

confidence: 99%

“…This is a kit containing 24 different types of odors in eight categories. The test result is reported as a number from 0 to 24, which determines the function of the sense of smell in the range of anosmia (0-9), severe microsmia [10] , [11] , [12] , [13] , mild microsmia [14] , [15] , [16] , [17] , [18] , and normosmia [19] , [20] , [21] , [14] . This measure was administered at baseline and the fourth week of the study.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial

Kasiri

Rouhani

Salehifar

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

The aim of this study was to evaluate the usage of mometasone furoate nasal spray in the recovery of patients with severe microsmia or anosmia induced by COVID-19. This was a prospective clinical trial on non-hospitalized adult patients with COVID-19 (> 18 years) who had severe microsmia or anosmia within two weeks. The subjects were randomly assigned to the mometasone furoate group (100 mcg twice daily) or sodium chloride group (0.9%); both groups also received olfactory training for 4 weeks. The primary outcome was the improvement of the olfactory score at the end of the study. Visual analog scale (VAS) and the University of Pennsylvania Smell Identification Test (UPSIT) were used to assess primary outcome. A total of 80 patients were recruited, 77 of them completed the study and were analyzed. There was no statistically significant difference in terms of demographics and baseline clinical characteristics. The olfactory scores (based on VAS) at weekly intervals showed a significant difference between the two groups (P:0.318, <0.001, <0.001, <0.001, respectively). The analyses also showed significant within-group differences from baseline. Nevertheless, the changes were not significant between the two groups (P: 0.444, 0.402, 0.267, 0.329). There was no significant difference between the two groups in terms of the UPSIT results (p> 0.239). However, a significant between-group difference was noted in the severity of loss of smell (P <0.001). Compared to olfactory training, mometasone furoate nasal spray combination with olfactory training showed a higher improvement in severe chronic anosmia by COVID-19.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial

Kasiri

Rouhani

Salehifar

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…Overall, there is no real evidence for any specific pharmacological option for the post-viral loss of smell including COVID-19. Some studies report an improvement in olfactory function following topical or systemic corticosteroid therapy (50,63). Olfactory training is the only current evidence-based therapeutic option for post-viral olfactory loss, with COVID-19 positive patients reporting an improvement in smell (45.6%) and taste (46.1%) at the time of the survey; in 90.6%, this was within 2 weeks of infection (64).…”

Section: Covid-19 Induced Taste and Smell Lossmentioning

confidence: 99%

Oral Mucosa, Saliva, and COVID-19 Infection in Oral Health Care

Atukorallaya

Ratnayake

2021

Front. Med.

View full text Add to dashboard Cite

The SARS-CoV-2 virus has shaken the globe with an ongoing pandemic of COVID-19 and has set challenges to every corner of the modern health care setting. The oral mucosa and saliva are high risk sites for higher viral loads and dental health care professionals are considered a high risk group. COVID-19-induced oral lesions and loss of taste and smell are common clinical complaints in the dental health care setting. The SARS-CoV-2 virus has been found to cause a wide range of non-specific oral mucosal lesions, but the specific diagnosis of these mucocutaneous lesions as COVID-19 lesions will facilitate the prevention of SARS-CoV-2 in dental health care settings and aid in proper patient management. The reported loss of taste and smell needs further investigation at the receptor level as it will give new insights into SARS-CoV-2 pathogenicity. The high yield of virus in the salivary secretion is a common finding in this infection and ongoing research is focusing on developing saliva as a rapid diagnostic fluid in COVID-19. In this review, we discuss the significance of oral mucosa, saliva and the relevance of the COVID-19 pandemic in dentistry.

show abstract

“…However, considering the involvement of all cranial nerves in COVID-19, we can suggest that the treatment of this disease was effective in healing nerve damage and reducing inflammation because we did not observe any significant permanent damage except loss of smell that did not regress for a long time. In this regard, the use of both nasal topical and systemic steroids was controversial [ 7 ].…”

mentioning

confidence: 99%